DENALI THERAPEUTICS INC. - COMMON STOCK

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

07 مايو 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

01 مايو 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

27 فبراير 2024 08:05:54 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces $500 million Private Placement Equity Financing

27 فبراير 2024 08:00:37 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

07 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

01 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

08 يناير 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

07 نوفمبر 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

30 أغسطس 2023 08:30:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

08 أغسطس 2023 16:01:27 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)

20 يونيو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

08 مايو 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting

10 أبريل 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

27 فبراير 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™

22 فبراير 2023 16:33:24 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™

15 فبراير 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi

25 يناير 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases

09 يناير 2023 08:00:44 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial

05 ديسمبر 2022 07:00:41 بحسب Nasdaq GlobeNewswire

Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

03 نوفمبر 2022 16:01:44 بحسب Nasdaq GlobeNewswire